On the other hand, Hegde et al. showed that in patients with RET-positive malignancies (medullary thyroid cancer, NSCLC and other types), time to progression was shorter when treated with ICIs compared to non-ICI therapy [20]. Here, RET is linked to medullary thyroid gland carcinoma.